跳至主要内容
临床试验/ACTRN12623001123639
ACTRN12623001123639尚未招募Unknown

Determining the optimal dose of omega-3 fatty acids in pregnancy for women with moderate status

South Australian Health and Medical Research Institute0 个研究点目标入组 300 人开始时间: 2023年10月31日最近更新:
适应症

试验速览

阶段
Unknown
状态
尚未招募
入组人数
300

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional
分配方式
Randomised controlled trial
主要目的
Treatment
盲法
Blinded (masking used)

入排标准

年龄范围
16 Years 至 o limit(—)
性别
Female

入选标准

  • Singleton pregnancy < 21 weeks gestation
  • Able to give informed consent
  • Randomised Controlled Trial (RCT) Groups only:
  • Identified as having an omega-3 fatty acid status in the lower end of the moderate range (defined as 3.7% to 4.0%% total fatty acids in serum)
  • Reference groups only:
  • Women with low omega-3 status (serum omega-3 <3.7% total fatty acids and supplemented with 800mg DHA + 100mg EPA per day)
  • OR Women with sufficient or replete status (serum omega-3 >4.3% total fatty acids) and taking no more than 250 mg per day of omega-3 from supplements.

排除标准

  • Allergy to fish
  • Enrolled in another fatty acid intervention trial throughout pregnancy.
  • Currently taking heparin (Clexane)

研究者

相似试验